Short Interest in BioStem Technologies, Inc. (OTCMKTS:BSEM) Increases By 32.3%

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 406,408 shares, a growth of 32.3% from the January 15th total of 307,219 shares. Based on an average daily trading volume, of 495,453 shares, the short-interest ratio is presently 0.8 days. Currently, 2.4% of the shares of the company are sold short. Currently, 2.4% of the shares of the company are sold short. Based on an average daily trading volume, of 495,453 shares, the short-interest ratio is presently 0.8 days.

BioStem Technologies Trading Up 5.1%

BSEM stock opened at $5.80 on Monday. The firm has a 50 day moving average of $4.96 and a 200-day moving average of $5.45. The firm has a market capitalization of $97.56 million, a P/E ratio of 6.82 and a beta of -0.39. BioStem Technologies has a 12 month low of $3.09 and a 12 month high of $15.74.

BioStem Technologies (OTCMKTS:BSEM) last released its quarterly earnings results on Thursday, November 13th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. The business had revenue of $10.47 million during the quarter, compared to analysts’ expectations of $55.20 million. Sell-side analysts predict that BioStem Technologies will post 1.41 EPS for the current year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.